Monograph

MAFDostarlimab [Jemperli] Concentrate For Infusion 500 mg/10 mL

Dostarlimab in combination with platinum-based chemotherapy, followed by dostarlimab as monotherapy, for untreated mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. Treatment with dostarlimab should be stopped at 3 years, or earlier if disease progresses.

MSHLDostarlimab Concentrate For Solution For Infusion 500 mg/10 mL

1) Monotherapy for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for recurrent or advanced MSI-H or dMMR endometrial cancer.
2) Dostarlimab in combination with platinum-based chemotherapy, followed by dostarlimab as monotherapy, for untreated mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. Treatment with dostarlimab should be stopped at 3 years, or earlier if disease progresses.
3) Dostarlimab in combination with platinum-based chemotherapy, followed by dostarlimab as monotherapy, for untreated primary advanced or recurrent endometrial cancer. Treatment with dostarlimab should be stopped at 3 years, or earlier if disease progresses.